Loading…
Loading…
TIHE (Taihe Group, Inc.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
TIHE does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for TIHE and 80,000+ other tickers.
See exactly how TIHE's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for TIHE and 80,000+ other tickers.
Currently, Taihe Group, Inc. is not engaged in substantial operational activities. Historically, the company functioned as a commercial laboratory, providing specialized predictive tests for chemosensitivity and immunotherapy on biopsy samples, alongside a variety of other laboratory services and products within the field of oncology. Established in 1994, the Scottsdale, Arizona-based entity was formerly known as NuOncology Labs, Inc. until it adopted the name Taihe Group, Inc. in April 2022.
No recent news available.